Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 173

1.

Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm.

Pemmaraju N, Lane AA, Sweet KL, Stein AS, Vasu S, Blum W, Rizzieri DA, Wang ES, Duvic M, Sloan JM, Spence S, Shemesh S, Brooks CL, Balser J, Bergstein I, Lancet JE, Kantarjian HM, Konopleva M.

N Engl J Med. 2019 Apr 25;380(17):1628-1637. doi: 10.1056/NEJMoa1815105.

PMID:
31018069
2.

Recognition of hemophagocytic lymphohistiocytosis in sickle cell vaso-occlusive crises is a potentially lifesaving diagnosis.

Leiva O, McMahon L, Sloan JM, Lee J, Lerner A.

Haematologica. 2019 Apr;104(4):e167-e169. doi: 10.3324/haematol.2018.206458. Epub 2019 Jan 31. No abstract available.

3.

High-dose melphalan and autologous peripheral blood stem cell transplantation in patients with AL amyloidosis and cardiac defibrillators.

Phull P, Sanchorawala V, Brauneis D, Sloan JM, Siddiqi OK, Quillen K, Sarosiek S.

Bone Marrow Transplant. 2019 Jan 21. doi: 10.1038/s41409-019-0440-5. [Epub ahead of print]

PMID:
30664726
4.

Induction Therapy with Bortezomib and Dexamethasone and Conditioning with High-Dose Melphalan and Bortezomib Followed by Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis: Long-Term Follow-Up Analysis.

Gupta VK, Brauneis D, Shelton AC, Quillen K, Sarosiek S, Sloan JM, Sanchorawala V.

Biol Blood Marrow Transplant. 2019 May;25(5):e169-e173. doi: 10.1016/j.bbmt.2019.01.007. Epub 2019 Jan 11.

PMID:
30639823
5.

Long-term outcome of kidney transplantation in AL amyloidosis.

Angel-Korman A, Stern L, Sarosiek S, Sloan JM, Doros G, Sanchorawala V, Havasi A.

Kidney Int. 2019 Feb;95(2):405-411. doi: 10.1016/j.kint.2018.09.021. Epub 2018 Dec 21.

PMID:
30580886
6.

Bortezomib ocular toxicities: Outcomes with ketotifen.

Dennis M, Maoz A, Hughes D, Sanchorawala V, Sloan JM, Sarosiek S.

Am J Hematol. 2019 Mar;94(3):E80-E82. doi: 10.1002/ajh.25382. Epub 2019 Jan 3. No abstract available.

PMID:
30575098
7.

Acute promyelocytic leukaemia presenting as necrotising fasciitis of the perineum (Fournier gangrene).

Furtado VF, Batalini F, Staziaki PV, Prilutskiy A, Sloan JM.

BMJ Case Rep. 2018 Dec 7;11(1). pii: e226837. doi: 10.1136/bcr-2018-226837.

PMID:
30567203
8.

Clustered incidence of adult acute promyelocytic leukemia.

Brunner AM, Kim PG, Sadrzadeh H, Drapkin BJ, Sprague KA, Sloan JM, Chai-Ho W, Bhargava P, Pozdnyakova O, Fathi AT.

Leuk Res. 2018 Nov;74:47-50. doi: 10.1016/j.leukres.2018.09.008. Epub 2018 Sep 19. No abstract available.

PMID:
30292128
9.

Modified High-Dose Melphalan and Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis.

Nguyen VP, Landau H, Quillen K, Brauneis D, Shelton AC, Mendelson L, Rahman H, Sloan JM, Sarosiek S, Sanchorawala V.

Biol Blood Marrow Transplant. 2018 Sep;24(9):1823-1827. doi: 10.1016/j.bbmt.2018.06.018. Epub 2018 Jun 20.

PMID:
29933072
10.

Heparin-induced thrombocytopenia and thrombosis during high dose melphalan and autologous stem cell transplantation.

Sarosiek S, Quillen K, Sloan JM, Brauneis D, Sanchorawala V.

Blood. 2018 Aug 16;132(7):755-757. doi: 10.1182/blood-2018-03-838672. Epub 2018 Jun 14. No abstract available.

PMID:
29903887
11.

High-dose melphalan and stem cell transplantation in AL amyloidosis with elevated cardiac biomarkers.

White PS, Phull P, Brauneis D, Sloan JM, Quillen K, Sarosiek S, Sanchorawala V.

Bone Marrow Transplant. 2018 Dec;53(12):1593-1595. doi: 10.1038/s41409-018-0242-1. Epub 2018 Jun 8. No abstract available.

PMID:
29884854
12.

Evaluation of a new continuous mononuclear cell collection procedure in a single transplant center cohort enriched for AL amyloidosis patients.

Pudusseri A, Smith I, Sarnacki D, Brauneis D, Shelton A, Sanchorawala V, Sloan JM, Sarosiek S, Quillen K.

Transfus Apher Sci. 2018 Jun;57(3):411-415. doi: 10.1016/j.transci.2018.04.025. Epub 2018 Apr 26.

PMID:
29731423
13.

Neuralgic amyotrophy following high-dose melphalan and autologous peripheral blood stem cell transplantation for AL amyloidosis.

Nguyen VP, Brauneis D, Kaku M, Sloan JM, Sarosiek S, Quillen K, Shelton AC, Sanchorawala V.

Bone Marrow Transplant. 2018 Mar;53(3):371-373. doi: 10.1038/s41409-017-0048-6. Epub 2017 Dec 21. No abstract available.

PMID:
29269794
14.

Association Between Hypercoagulable Conditions and Calciphylaxis in Patients With Renal Disease: A Case-Control Study.

Dobry AS, Ko LN, St John J, Sloan JM, Nigwekar S, Kroshinsky D.

JAMA Dermatol. 2018 Feb 1;154(2):182-187. doi: 10.1001/jamadermatol.2017.4920.

15.

High-Dose Melphalan and Stem Cell Transplantation in Patients on Dialysis Due to Immunoglobulin Light-Chain Amyloidosis and Monoclonal Immunoglobulin Deposition Disease.

Batalini F, Econimo L, Quillen K, Sloan JM, Sarosiek S, Brauneis D, Havasi A, Stern L, Dember LM, Sanchorawala V.

Biol Blood Marrow Transplant. 2018 Jan;24(1):127-132. doi: 10.1016/j.bbmt.2017.08.031. Epub 2017 Sep 1.

16.

The incidence of atrial fibrillation among patients with AL amyloidosis undergoing high-dose melphalan and stem cell transplantation: experience at a single institution.

Arun M, Brauneis D, Doros G, Shelton AC, Sloan JM, Quillen K, Ruberg FL, Sanchorawala V, Varga C.

Bone Marrow Transplant. 2017 Sep;52(9):1349-1351. doi: 10.1038/bmt.2017.148. Epub 2017 Jul 24. No abstract available.

PMID:
28737773
17.

Thrombotic Microangiopathy: A Multidisciplinary Team Approach.

Gordon CE, Chitalia VC, Sloan JM, Salant DJ, Coleman DL, Quillen K, Ravid K, Francis JM.

Am J Kidney Dis. 2017 Nov;70(5):715-721. doi: 10.1053/j.ajkd.2017.05.017. Epub 2017 Jul 15.

PMID:
28720207
18.

Hematologic relapse in AL amyloidosis after high-dose melphalan and stem cell transplantation.

Browning S, Quillen K, Sloan JM, Doros G, Sarosiek S, Sanchorawala V.

Blood. 2017 Sep 14;130(11):1383-1386. doi: 10.1182/blood-2017-06-788729. Epub 2017 Jul 11. No abstract available.

19.

Adult T-cell Leukemia/Lymphoma: A Problem Abroad and at Home.

Dittus C, Sloan JM.

Hematol Oncol Clin North Am. 2017 Apr;31(2):255-272. doi: 10.1016/j.hoc.2016.11.005. Review.

PMID:
28340877
20.

Extranodal Marginal Zone Endobronchial Lymphoma Associated With Hepatitis C.

Bhatt N, Sloan JM, O'Hara CJ, Oommen R, Steiling K, Litle VR.

Ann Thorac Surg. 2016 Nov;102(5):e407-e408. doi: 10.1016/j.athoracsur.2016.04.060.

PMID:
27772593
21.

Association Between Inferior Vena Cava Filter Insertion in Trauma Patients and In-Hospital and Overall Mortality.

Sarosiek S, Rybin D, Weinberg J, Burke PA, Kasotakis G, Sloan JM.

JAMA Surg. 2017 Jan 1;152(1):75-81. doi: 10.1001/jamasurg.2016.3091.

PMID:
27682367
22.

Pomalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 1 and 2 trial.

Sanchorawala V, Shelton AC, Lo S, Varga C, Sloan JM, Seldin DC.

Blood. 2016 Aug 25;128(8):1059-62. doi: 10.1182/blood-2016-04-710822. Epub 2016 Jul 5.

23.

Improving the retrieval rate of inferior vena cava filters with a multidisciplinary team approach.

Inagaki E, Farber A, Eslami MH, Siracuse JJ, Rybin DV, Sarosiek S, Sloan JM, Kalish J.

J Vasc Surg Venous Lymphat Disord. 2016 Jul;4(3):276-82. doi: 10.1016/j.jvsv.2015.11.002. Epub 2016 Feb 28.

24.

The Effect of Bone Marrow Plasma Cell Burden on Survival in Patients with Light Chain Amyloidosis Undergoing High-Dose Melphalan and Autologous Stem Cell Transplantation.

Dittus C, Uwumugambi N, Sun F, Sloan JM, Sanchorawala V.

Biol Blood Marrow Transplant. 2016 Sep;22(9):1729-1732. doi: 10.1016/j.bbmt.2016.05.027. Epub 2016 Jun 11.

25.

Surgical Management of Pulmonary Mucosa-Associated Lymphoid Tissue Lymphoma Associated With Light-Chain Deposition Disease.

Muñoz-Largacha JA, O'Hara CJ, Sloan JM, Fernando HC, Litle VR.

Ann Thorac Surg. 2016 Jun;101(6):e207-10. doi: 10.1016/j.athoracsur.2015.10.089.

PMID:
27211983
26.

Effect of severe hypoalbuminemia on toxicity of high-dose melphalan and autologous stem cell transplantation in patients with AL amyloidosis.

Lee SY, Meehan RS, Seldin DC, Sloan JM, Quillen K, Shelton A, Brauneis D, Sanchorawala V.

Bone Marrow Transplant. 2016 Oct;51(10):1318-1322. doi: 10.1038/bmt.2016.132. Epub 2016 May 16.

PMID:
27183092
27.

Clinical presentation and treatment responses in IgM-related AL amyloidosis.

Sissoko M, Sanchorawala V, Seldin D, Sworder B, Angelino K, Broce M, Berk J, Sloan JM.

Amyloid. 2015;22(4):229-35. doi: 10.3109/13506129.2015.1092433. Epub 2015 Oct 21.

PMID:
26488936
28.

Risk factors for venous thromboembolism in immunoglobulin light chain amyloidosis.

Bever KM, Masha LI, Sun F, Stern L, Havasi A, Berk JL, Sanchorawala V, Seldin DC, Sloan JM.

Haematologica. 2016 Jan;101(1):86-90. doi: 10.3324/haematol.2015.133900. Epub 2015 Oct 9.

29.

Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience.

Sanchorawala V, Sun F, Quillen K, Sloan JM, Berk JL, Seldin DC.

Blood. 2015 Nov 12;126(20):2345-7. doi: 10.1182/blood-2015-08-662726. Epub 2015 Oct 6. No abstract available.

30.

Complete Genome Sequence of Caulobacter crescentus Siphophage Seuss.

Sloan JM, Keene JL, Cahill JL, Rasche ES, Kuty Everett GF.

Genome Announc. 2015 Oct 1;3(5). pii: e01132-15. doi: 10.1128/genomeA.01132-15.

31.

Iron-Deficiency Anemia.

Wilson K, Sloan JM.

N Engl J Med. 2015 Jul 30;373(5):485. doi: 10.1056/NEJMc1507104. No abstract available.

PMID:
26222575
32.

Association between kidney function, rehabilitation outcome, and survival in older patients discharged from inpatient rehabilitation.

Doyle EM, Sloan JM, Goodbrand JA, McMurdo ME, Donnan PT, McGilchrist MM, Frost H, Witham MD.

Am J Kidney Dis. 2015 Nov;66(5):768-74. doi: 10.1053/j.ajkd.2015.04.041. Epub 2015 Jun 2.

PMID:
26048443
33.

Kidney transplantation in patients with history of malignancy: Time to rethink the guidelines?

Baiyee E, Sloan JM.

Front Biosci (Elite Ed). 2015 Jun 1;7:491-500. Review.

PMID:
25961427
34.

Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Amyloidosis: Results of a Prospective Clinical Trial.

Sanchorawala V, Brauneis D, Shelton AC, Lo S, Sun F, Sloan JM, Quillen K, Seldin DC.

Biol Blood Marrow Transplant. 2015 Aug;21(8):1445-51. doi: 10.1016/j.bbmt.2015.04.001. Epub 2015 Apr 6.

35.

Hospital admissions following outpatient administration of high-dose melphalan and autologous SCT for AL amyloidosis.

Freeman B, Brauneis D, Seldin DC, Quillen K, Sloan JM, Renteria AS, Shelton AC, Teschner T, Finn KT, Sanchorawala V.

Bone Marrow Transplant. 2014 Oct;49(10):1345-6. doi: 10.1038/bmt.2014.132. Epub 2014 Jun 23. No abstract available.

PMID:
24955784
36.

Hematopoietic cell transplantation for plasmablastic lymphoma: a review.

Al-Malki MM, Castillo JJ, Sloan JM, Re A.

Biol Blood Marrow Transplant. 2014 Dec;20(12):1877-84. doi: 10.1016/j.bbmt.2014.06.009. Epub 2014 Jun 16. Review.

37.

Simultaneous presentation of kappa-restricted chronic lymphocytic leukemia and lambda light chain AL amyloidosis.

von Keudell G, Sanchorawala V, O'Hara C, C Seldin D, Sloan JM.

Amyloid. 2014 Jun;21(2):124-7. doi: 10.3109/13506129.2013.854205. Epub 2014 Jan 29.

PMID:
24471777
38.

Molecular effects of autoimmune-risk promoter polymorphisms on expression, exon choice, and translational efficiency of interferon regulatory factor 5.

Clark DN, Lambert JP, Till RE, Argueta LB, Greenhalgh KE, Henrie B, Bills T, Hawkley TF, Roznik MG, Sloan JM, Mayhew V, Woodland L, Nelson EP, Tsai MH, Poole BD.

J Interferon Cytokine Res. 2014 May;34(5):354-65. doi: 10.1089/jir.2012.0105. Epub 2013 Dec 18.

PMID:
24350899
39.

Acquired Glanzmann thrombasthenia associated with Hodgkin lymphoma: rapid reversal of functional platelet defect with ABVD (adriamycin/bleomycin/vinblastine/dacarbazine) chemotherapy.

Raman V, Quillen K, Sloan JM.

Clin Lymphoma Myeloma Leuk. 2014 Apr;14(2):e51-4. doi: 10.1016/j.clml.2013.10.004. Epub 2013 Nov 14. No abstract available.

PMID:
24342105
40.

Safety and efficacy of high-dose melphalan and auto-SCT in patients with AL amyloidosis and cardiac involvement.

Girnius S, Seldin DC, Meier-Ewert HK, Sloan JM, Quillen K, Ruberg FL, Berk JL, Doros G, Sanchorawala V.

Bone Marrow Transplant. 2014 Mar;49(3):434-9. doi: 10.1038/bmt.2013.192. Epub 2013 Dec 9.

PMID:
24317129
41.

Indications, complications, and management of inferior vena cava filters: the experience in 952 patients at an academic hospital with a level I trauma center.

Sarosiek S, Crowther M, Sloan JM.

JAMA Intern Med. 2013 Apr 8;173(7):513-7. doi: 10.1001/jamainternmed.2013.343.

PMID:
23552968
42.

High-dose melphalan and stem cell transplantation for patients with AL amyloidosis: trends in treatment-related mortality over the past 17 years at a single referral center.

Tsai SB, Seldin DC, Quillen K, Berk JL, Ruberg FL, Meier-Ewert H, Sloan JM, Doros G, Finn KT, Skinner M, Sanchorawala V.

Blood. 2012 Nov 22;120(22):4445-6. doi: 10.1182/blood-2012-09-457341. No abstract available.

43.

Successful long-term management of aneurysm-associated chronic disseminated intravascular coagulation with low molecular weight heparin.

Perry JH, Lazar HL, Quillen K, Sloan JM.

J Card Surg. 2012 Nov;27(6):730-5. doi: 10.1111/jocs.12010.

PMID:
23173861
44.

Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trial.

Sanchorawala V, Patel JM, Sloan JM, Shelton AC, Zeldis JB, Seldin DC.

Haematologica. 2013 May;98(5):789-92. doi: 10.3324/haematol.2012.075192. Epub 2012 Nov 9.

45.

Multiple arterial and venous thromboembolic complications in AL amyloidosis and cardiac involvement: a case report and literature review.

Freeman B, Sloan JM, Seldin DC, Cowan AJ, Ruberg FL, Sanchorawala V.

Amyloid. 2012 Sep;19(3):156-60. doi: 10.3109/13506129.2012.694825. Epub 2012 Jun 11. Review.

PMID:
22680044
46.

Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue with amyloid deposition: a clinicopathologic case series.

Ryan RJ, Sloan JM, Collins AB, Mansouri J, Raje NS, Zukerberg LR, Ferry JA.

Am J Clin Pathol. 2012 Jan;137(1):51-64. doi: 10.1309/AJCPI08WAKYVLHHA.

PMID:
22180478
47.

Bortezomib and high-dose melphalan conditioning for stem cell transplantation for AL amyloidosis: a pilot study.

Sanchorawala V, Quillen K, Sloan JM, Andrea NT, Seldin DC.

Haematologica. 2011 Dec;96(12):1890-2. doi: 10.3324/haematol.2011.049858. Epub 2011 Aug 22. No abstract available.

48.

High-dose melphalan and autologous stem cell transplantation for AL amyloidosis: recent trends in treatment-related mortality and 1-year survival at a single institution.

Seldin DC, Andrea N, Berenbaum I, Berk JL, Connors L, Dember LM, Doros G, Fennessey S, Finn K, Girnius S, Lerner A, Libbey C, Meier-Ewert HK, O'Connell R, O'Hara C, Quillen K, Ruberg FL, Sam F, Segal A, Shelton A, Skinner M, Sloan JM, Wiesman JF, Sanchorawala V.

Amyloid. 2011 Jun;18 Suppl 1:127-9. doi: 10.3109/13506129.2011.574354047. No abstract available. Erratum in: Amyloid. 2011 Jun;18 Suppl 1:129.

49.

Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients.

Cibeira MT, Sanchorawala V, Seldin DC, Quillen K, Berk JL, Dember LM, Segal A, Ruberg F, Meier-Ewert H, Andrea NT, Sloan JM, Finn KT, Doros G, Blade J, Skinner M.

Blood. 2011 Oct 20;118(16):4346-52. doi: 10.1182/blood-2011-01-330738. Epub 2011 Aug 9.

50.

Antineutrophil cytoplasmic antibodies, autoimmune neutropenia, and vasculitis.

Grayson PC, Sloan JM, Niles JL, Monach PA, Merkel PA.

Semin Arthritis Rheum. 2011 Dec;41(3):424-33. doi: 10.1016/j.semarthrit.2011.02.003. Epub 2011 Apr 19.

Supplemental Content

Loading ...
Support Center